Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Diamond Therapeutics Inc. is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, meaning each matter is being reviewed by a different individual. These examiners are located within 2 distinct art units, suggesting a focused technical scope for the company's filings.
GONZALEZ, LUISALBERTO is identified as the busiest examiner for the portfolio, holding 1 pending office action. Since there are 4 pending office actions and 4 distinct examiners, the workload is distributed with 1 action per examiner. This requires the applicant to adapt to 4 different examiner styles while navigating the standards of 2 distinct art units.
The presence of 4 pending office actions across 2 distinct art units indicates that the company's innovations are being evaluated by multiple specialized groups. With 4 distinct examiners involved, practitioners must manage a variety of individual preferences and procedural expectations. This level of activity shows an ongoing effort to secure patent protection across related Biotechnology & Pharmaceuticals technical areas.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 59.4% | +47.2% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| BAILEY, STEVEN WILLIAM | 1 | 31.6% | +15.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18501238 | 5-HT2A AND/OR 5-HT2C RECEPTOR AGONISTS | HABTE, KAHSAY | — |
| 18461776 | 5-HT RECEPTOR AGONIST TITRATION | BAILEY, STEVEN WILLIAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19030518 | AMORPHOUS (A-POLYMORPHIC) PSILOCYBIN | GONZALEZ, LUISALBERTO | — |
| 18813959 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | COPPINS, JANET L | — |
| 18461776 | 5-HT RECEPTOR AGONIST TITRATION | BAILEY, STEVEN WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19030518 | AMORPHOUS (A-POLYMORPHIC) PSILOCYBIN | GONZALEZ, LUISALBERTO | 1624 | §103 | Final Rejection | — | Pending | Jan 17, 2025 |
| 18813959 | COMPOSITIONS AND METHODS FOR IMPROVING COGNITIVE FUNCTION | COPPINS, JANET L | 1628 | §103 | Final Rejection | — | Pending | Aug 23, 2024 |
| 18501238 | 5-HT2A AND/OR 5-HT2C RECEPTOR AGONISTS | HABTE, KAHSAY | 1624 | §102§112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18461776 | 5-HT RECEPTOR AGONIST TITRATION | BAILEY, STEVEN WILLIAM | — | §101§102§103§112 | Non-Final OA | — | Pending | Sep 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial